Two Sigma Advisers
RXRX icon

Two Sigma Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History

Two Sigma Advisers’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-313,945
Closed -$1.28M – 1738
2025
Q4 		$1.28M Sell
313,945
-501,500
-62% -$2.48M ﹤0.01% 1360
2025
Q3 		$3.98M Buy
+815,445
New +$4.28M 0.01% 823
2025
Q2 		– Sell
-95,445
Closed -$505K – 2511
2025
Q1 		$505K Sell
95,445
-356,300
-79% -$2.6M ﹤0.01% 1775
2024
Q4 		$3.05M Sell
451,745
-38,155
-8% -$257K 0.01% 923
2024
Q3 		$3.23M Buy
489,900
+54,100
+12% +$388K 0.01% 862
2024
Q2 		$3.27M Buy
435,800
+250,700
+135% +$2.19M 0.01% 946
2024
Q1 		$1.85M Buy
185,100
+153,400
+484% +$1.71M ﹤0.01% 1270
2023
Q4 		$313K Buy
+31,700
New +$226K ﹤0.01% 2088
2023
Q2 		– Sell
-15,400
Closed -$103K – 2622
2023
Q1 		$103K Buy
+15,400
New +$122K ﹤0.01% 2380
2022
Q2 		– Sell
-40,100
Closed -$287K – 2853
2022
Q1 		$287K Buy
+40,100
New +$426K ﹤0.01% 2241

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Advisers's RXRX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 313,945 shares — an estimated $1.28M sold.

Two Sigma Advisers first reported a position in RXRX in Q1 2022 and held it in 10 quarters. The position peaked at $3.98M in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 313,945 Recursion Pharmaceuticals shares in Q1 2026, an estimated $1.28M.
  • Two Sigma Advisers first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 10 quarters.
  • Two Sigma Advisers's Recursion Pharmaceuticals position peaked at $3.98M in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.